NXP031

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

1.	Neuroinflammatory Diseases 01/01/2021 - "We further found that NXP031 increased plasma ascorbic acid levels and inhibited microglia activation-induced neuroinflammation in the SN, which might contribute to the protective effects of NXP031 on nigrostriatal degeneration. "
2.	Synucleinopathies 01/01/2022 - "The objective of this study was to evaluate whether NXP031, a new compound we developed consisting of Aptamin C and Vitamin C, is neuroprotective against α-synucleinopathy. "
3.	Parkinson Disease (Parkinson's Disease) 01/01/2022 - "NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-α-synuclein mouse model of Parkinson's disease." 01/01/2021 - "Neuroprotective effect of NXP031 in the MPTP-induced Parkinson's disease model."
4.	Cognitive Dysfunction 06/11/2021 - "NXP031 administration alleviates cognitive impairment, microglial activity, and oxidative stress after CCH. " 06/11/2021 - "NXP031 Improves Cognitive Impairment in a Chronic Cerebral Hypoperfusion-Induced Vascular Dementia Rat Model through Nrf2 Signaling."
5.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 06/11/2021 - "NXP031 Improves Cognitive Impairment in a Chronic Cerebral Hypoperfusion-Induced Vascular Dementia Rat Model through Nrf2 Signaling."

1.	Ascorbic Acid (Vitamin C)
2.	Synucleins
3.	Neuroprotective Agents
4.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)